| Literature DB >> 23096155 |
S Muhie1, R Hammamieh, C Cummings, D Yang, M Jett.
Abstract
Transcriptome alterations of leukocytes from soldiers who underwent 8 weeks of Army Ranger training (RASP, Ranger Assessment and Selection Program) were analyzed to evaluate impacts of battlefield-like stress on the immune response. About 1400 transcripts were differentially expressed between pre- and post-RASP leukocytes. Upon functional analysis, immune response was the most enriched biological process, and most of the transcripts associated with the immune response were downregulated. Microbial pattern recognition, chemotaxis, antigen presentation and T-cell activation were among the most downregulated immune processes. Transcription factors predicted to be stress-inhibited (IRF7, RELA, NFκB1, CREB1, IRF1 and HMGB) regulated genes involved in inflammation, maturation of dendritic cells and glucocorticoid receptor signaling. Many altered transcripts were predicted to be targets of stress-regulated microRNAs. Post-RASP leukocytes exposed ex vivo to Staphylococcal enterotoxin B showed a markedly impaired immune response to this superantigen compared with pre-RASP leukocytes, consistent with the suppression of the immune response revealed by transcriptome analyses. Our results suggest that suppression of antigen presentation and lymphocyte activation pathways, in the setting of normal blood cell counts, most likely contribute to the poor vaccine response, impaired wound healing and infection susceptibility associated with chronic intense stress.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23096155 PMCID: PMC3564018 DOI: 10.1038/gene.2012.49
Source DB: PubMed Journal: Genes Immun ISSN: 1466-4879 Impact factor: 2.676
Figure 1Differential and complete leukocyte counts of soldiers before and after RASP. Differential and complete blood counts for pre- and post-RASP subjects included red blood cells (RBC), white blood cells (WBC), neutrophils (NEU), lymphocytes (LYM), monocytes (MON), eosinophils (EOS) and basophils (BAS). Using comparative t-test, only RBC (P<0.006) and BAS (P<0.02) were significantly changed (reduced) after RASP. The ranges of cell counts including RBC and BAS (shown by the vertical lines) were within normal ranges. Normal ranges are WBC 5–12 × 103 mm−3; NEU 2–8 × 103 mm−3; LYM 1–5 × 103 mm−3; MON 0.1–1 × 103 mm−3; EOS 0.0–0.4 × 103 mm−3; BAS 0.0–0.2 × 103 mm−3.
Figure 2Heat map of differentially expressed genes in leukocytes of soldiers before and after RASP. Heat map shows hierarchical clustering of 288 genes that passed Welch's t-test with FDR correction (q<0.001) and had expression alteration of ⩾1.5-fold. Each lane shows the 288 genes and their leukocyte expression level for each subject before (left panel) or after (right panel) RASP in comparison to human universal reference RNA.
Functions significantly associated with differentially regulated immune response genes that passed Welch's t-test and FDR correction (q<0.05) and showed >1.3-fold change in post-RASP leukocytes compared with pre-RASP leukocytes
| 45321 | Leukocyte activation | MICA, CD8A, CD8B, ELF4, TLR4, ADA, CD74, CD93, CD2, FCER1G, CD4, SYK, IL4, KLF6, PTPRC, CD3D, IL8, CD3E, RELB, SLAMF7, CD40, LAT, LCK, CD79A, LCP2 | ||
| 6954 | Inflammatory response | CXCL1, ITGAL, TNF, TLR2, NFKB1, ITGB2, TLR4, CCL5, CD97, CCL20, KRT1, IL1B, IL1A, CEBPB, IL8, IL1RN, GRO3, CD40, CCL18, CD180, C8G, SCYA7, CCL13, CCR7, CYBB, CCR5, CRH, CD14 | ||
| 19882 | Antigen processing and presentation | HLA-DQB1, MICA, CD8A, HLA-DRB1, RELB, HLA-C, FCGRT, HLA-B, HLA-G, CD74, B2M, FCER1G, HLA-DPA1, HLA-DPB1, HLA-DOB, AP3B1, HLA-DRA | ||
| 46649 | Lymphocyte activation | IL4, PTPRC, KLF6, MICA, CD3D, CD8A, ELF4, CD3E, CD8B, RELB, CD40, SLAMF7, CD74, ADA, LCK, CD2, CD4, CD79A, SYK | ||
| 30097 | Hemopoiesis | IL4, PTPRC, KLF6, CD3D, LYN, HCLS1, RELB, IFI16, MYH9, CD164, CD74, LCK, CD4, SPIB, CD79A, MYST1, SYK, MYST3 | ||
| 52033 | Pathogen-associated molecular pattern recognition | PF4, CHIT1, TLR2, TLR4, SCYA7, CD14, PF4V1, CLP1, TICAM1, FPRL1, FPR1 | ||
| 6935 | Chemotaxis | IL4, CXCL1, C5AR1, IL8, GRO3, ITGB2, PF4, CCL5, CCL18, SCYB5, SCYA7, CCL13, CCR7, CCR5, PPBP, CCL20, IL1B, FCER1G, SYK | ||
| 42110 | T-cell activation | PTPRC, MICA, CD3D, CD8A, CD3E, CD8B, ELF4, RELB, CD74, ADA, LCK, CD2, CD4, SYK | ||
| 2274 | Myeloid leukocyte activation | LAT, IL8, CD93, RELB, FCER1G, TLR4, LCP2 | ||
| 50778 | Positive regulation of immune response | PTPRC, MICA, SLK, FYN, KRT1, TLR2, FCER1G, CD79A, C8G, SYK | ||
| 6959 | Humoral immune response | PSMB10, CD83, ST6GAL1, TNF, HLXB9, POU2F2, KRT1, AIRE, C8G | ||
| 1934 | Positive regulation of phosphorylation | TNF, CCND3, LYN, HCLS1, IL1B, CD4, SYK | ||
| 45087 | Innate immune response | CYBB, IL1R1, SARM1, CLP1, KRT1, TLR2, TLR4, SLAMF7, CD180, C8G | ||
| 2252 | Immune effector process | PTPRC, LAT, MICA, FCN2, KRT1, FCER1G, SLAMF7, CD74, C8G | ||
| 30593 | Neutrophil chemotaxis | IL8, FCER1G, IL1B, ITGB2, SYK | ||
| 7229 | Integrin signaling | LAT, ITGAL, ITGAX, ITGB2, MYH9, ITGAM, SYK | ||
| 45058 | T-cell selection | CD3D, CD4, CD74, SYK | ||
| 1816 | Cytokine production | IL4, CD4, ISGF3G, CD226, LCP2 | ||
| 6909 | Phagocytosis | CD93, FCN2, CLP1, FCER1G, CD14 | ||
| 2460 | Somatic recombination for adaptive response | IL4, RELB, FCER1G, TLR4, CD74, C8G | ||
| 48545 | Response to steroid hormones | CEBPA, CAV1, HMGB2, PRKACA, CD24 | ||
| 42326 | Negative regulation of phosphorylation | CAV1, PRKACA, INHA | ||
| 6956 | Complement activation | C4B, C3, C2 | ||
| 10817 | Regulation of hormone levels | DHRS2, ACE, FKBP1B | ||
| 43434 | Response to peptide hormones | HHEX, PRKDC, PRKACA | ||
| 2762 | Negative regulation of myeloid leukocyte differentiation | FSTL3, INHA | ||
| 32088 | Negative regulation of NFκB activity | POP1, SIVA | ||
| 51384 | Response to glucocorticoids | CEBPA, CAV1, PRKACA | ||
| 16481 | Negative regulation of transcription | CEBPA, HHEX, CAV1, HMGB2, FST, HELLS | ||
Figure 3Comparison of transcript levels determined by two different assays and comparison of transcript levels with plasma protein levels. (a) Correlation of real-time QPCR and cDNA microarray data: real-time PCR reactions for each gene were carried out with three or more replicates. Trizol RNA isolation and cDNA microarrays were used. Significance levels: *0.001⩽q<0.05, **1.0E-5⩽q<0.001, ***q<1.0E-5—q stands for P-values after FDR correction. (b) Plasma protein concentrations (ELISA) compared with transcript levels (oligo and cDNA microarray): plasma concentrations of PRL, IGF1 and IGF2, TNFα and enzymatic activity of superoxide dismutase 1 (SOD1) assays were performed in triplicate on the plasma of 9 of the 10 soldiers who completed RASP. The IGF-I depletion is consistent with the finding of other investigators who measured its plasma concentration on similar subjects[15] (*0.01⩽P<0.05, **0.001⩽P<0.01, ***P<0.001).
Figure 4Expression of immune response genes in leukocytes exposed ex vivo to SEB. Leukocytes isolated from whole blood were treated with SEB (∼106 cells ml−1 in RPMI 1640 and 10% human AB serum at a final concentration of 100 ng ml−1 SEB). Total RNA was isolated using Trizol and expression levels were profiled using cDNA microarrays. Shown here are the 151 RASP-suppressed immune response genes that passed Welch's test and FDR correction (q<0.05). (a) Lanes left to right: pre-RASP samples not exposed to SEB (control), pre-RASP samples exposed to SEB, post-RASP samples not treated with SEB, post-RASP samples exposed to SEB. For comparative visualization purpose, expression values of the other groups were transformed against the pre-RASP control samples (black lane). Heat map of the same data without transformation is given in the supplement (Supplementary Figure S5). (b) Expression values in SEB exposed leukocytes (in both the pre- and post-RASP conditions) were compared with the corresponding SEB untreated groups (pre-RASP control and post-RASP stressed groups). (c) Heat map of the 151 immune response genes in SEB treated groups (in both pre- and post-RASP leukocytes) clustered after subtraction of the corresponding baseline responses (cluster after subtraction of their expressions in the corresponding untreated groups shown in Figure 4b). Figure 4c clearly shows poor response of post-RASP leukocytes towards SEB exposure compared with pre-RASP leukocytes.
Figure 5Predicted and experimentally observed targets of RASP-regulated microRNAs. (a) Heat map of differentially regulated 57 microRNAs that passed Welch's T-test (P<0.1) and 1.3-fold change. Most (46 of 57) miRs were downregulated, and 11 miRs were upregulated in post-RASP leukocytes. (b) Predicted or experimentally observed targets of 39 of the 57 RASP-regulated miRs. Shown here are 112 RASP regulated immune response transcripts as targets of the 39 of 57 miRs. (Note: let-7a-5p is synonym for mature let-7f). Many of the miR-155 and let-7f targets were excluded for simplification and are shown next. The top functions and pathways associated with 112 target transcripts are: (I) transcription of immune response genes, communication between innate and adaptive immune cells, activation and proliferations of leukocytes, glucocorticoid receptor signaling; and (II) inflammatory response, chemotaxis, maturation of DC, communication between DC and NK cells, hemopoisis, regulation of activated leukocytes, pattern-recognition receptors and acute phase response signaling. Overall, most RASP-suppressed miRs were significantly associated with inflammatory response, and activation and proliferation of leukocytes.
Figure 6Predicted targets of miR-155 and let-7f families. (a) Expression levels of hsa-miR-155 and hsa-let-7f in pre-RASP (control), post-RASP (stressed) and pre-RASP exposed to SEB, and post-RASP exposed to SEB groups. Sequences of mature miR-155 and let-7f are also shown. (b) Regulatory target genes and modulators of miR-155 and let-7f families were identified from 1396 differentially expressed transcripts that passed Welch's t-test, FDR correction (q<0.05) and 1.5-fold filters. MiR-155 is connected to inflammatory cytokines (IL-1A,-1B, -8, TNF) and transcription factors (IRF7 and NFKB1). Solid lines represent direct and broken lines indirect regulatory connections. Enriched pathways included glucocorticoid receptor signaling, dendritic cell (DC) maturation, bacterial and viral pattern recognition, cross talk between DC and NK cells, TREM1 signaling, acute phase response signaling, and communication between innate and adaptive immunity. Others showed that in response to lipopolysaccharides (LPS), miR-155 is highly upregulated in human monocyte-derived DCs, and suppresses inflammatory cytokines of the TLR/IL-1 pathway acting as a negative feedback loop control.[25] In another study, it regulates the production of inflammatory cytokines by targeting C/EBPbeta (CEBPB) in tumor-associated macrophages.[26, 27] Monk et al. and others observed that the family of NFκBs and IRFs are necessary for the transcription of pri-miR-155, and its expression is modulated by the TLRs and MAPK signaling molecules[28, 29] Upregulation of miR-155 in spite of suppression of the up-stream inducers of miR-155 indicate the presence of other regulators that induce expression of miR-155 under battlefield-like stress.
Predicted transcription factors and targets identified among 1396 genes that passed Welch's t-test, FDR correction (q⩽0.05) and 1.5-fold change cutoff
| P | |||
|---|---|---|---|
| 3.1 | 4.1E-04 | CASP1, CDKN1A, CEBPA, GUSB, ICAM1, IL1A, IL1B, IL8, IRF1, MMP7, NFKB1, NFKB2, RELA, RELB, TRAF3 | |
| 3 | 1.6E-17 | ACAT1, ACTB, ACTN1, AFP, AHCY, ALB, BCAT1, BCL6, BIN1, BIRC2, BIRC5, CAPN2, CASP1 CASP10, CAV1, CCND1, CCND3, CD44, CD48, CDC20, CDH2, CDK1, CDK11A/CDK11B, CDKN1A, CEBPA, COL14A1, COL1A1, CSPG4, CYFIP2, DDX11/DDX12, DDX3X, DDX5, DUSP6, EDN1, EGR2, EIF2S2, F2, F3, FBN1 | |
| 2.8 | 4.8E-05 | BIRC5, CCND1, CDC20, CDK1, CDKN1A, CENPA, CENPF, FOXM1, KDR, KIF20A, MMP2, PLK4, TGFBR2 | |
| 2.7 | 3.2E-02 | CCL5, CCND1, CDK1, CDKN1A, IL1B, ITGB1, KRT1, KRT17, PTCH1, SFRP1 | |
| 2.4 | 1.4E-03 | BCL6, CDKN1A, EDN1, FTH1, ID1, KLF6, LAMP2, MTHFD1, PDGFRB, SERINC3, TSC2, UBE2C | |
| 2.1 | 3.6E-02 | ABCC2, AFP, AKR1C4, ALB, ANPEP, APOB, AQP9, BCL6, C2, CCND1, DPP4, DUSP6, FAM107B, FBXO8, FGA, FGB, G0S2, GNB2L1, HNF4A, IGFBP1, KIF20A, KIR3DL1, LCAT, MTHFD1, NAPA, PDK1, PFKP, PIH1D1, PRLR, PZP, SERPINA7, SLC26A1, SLCO1A2, SSTR4, TRA@, UQCRC2, UROD | |
| −2.2 | 1.3E-11 | ACTG2, ALB, C3, CCL5, CCND1, CD14, CDKN1A, CEBPA, CEBPB, COL1A1, CP, CSF1R, CTSC, CXCL5, CYP19A1, DDX5, DEGS1, FTL, HLA-C, HP, HSPD1, ICAM1, ID1, IGFBP1, IL1B, IL1RN, IL8, INMT, IRF9, LAMC1, LCP2, LYN, MGP, MIA, PCTP, PDGFRA, PEA15, PLAUR, PPARD, PRKCD, PR | |
| −2.3 | 2.8E-03 | ACLY, CAV1, CCND1, CD68, CDC20, COL1A1, CYP19A1, FTH1, MMP2, MVD, NCF2, PTBP2, RELB, SCD | |
| −2.4 | 1.4E-07 | B2M, CCND1, CD74, COL1A1, HLA-B, HLA-DOB, HLA-DPA1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1 | |
| −2.6 | 3.4E-03 | BCL6, CCND3, CD79A, CD79B, IGHA1, IGHG1, LCK, TRAF3 | |
| −2.8 | 8.2E-12 | A2M, B2M, BIRC5, BTG1, C3, CASP1, CASP2, CASP4, CCL5, CCND1, CCND3, CCR7, CD14, CDKN1A, DPP4, FCER1G, GATA3, GBP1, GZMB, HLADRB1, ICAM1, IFIT3, IL1B, IL8, IRF1, IR5, IRF7, IRF9, LY96, NFE2, PDGFRB, PF4, PRL, PSMB10, PTGS2, SMAD7, SOCS3, STAT2, TLR4, TN | |
| −2.8 | 1.8E-04 | BIRC5, CCND1, CDKN1A, CTGF, CYR61, FOXM1, FOXO1, GPX1, IER3, IGFBP1, IL8, NAMPT, NOS3, SATB1, SOD2, TNFRSF1B, TXNIP, UBC, UBE2C | |
| −2.9 | 1.5E-10 | ACTB, CCR7, CD14, CD68, CD79A, CD79B, CEBPA, CSF1R, CYBB, DUSP6, FCER1G, FLI1, FTH1, GNB2L1, GPX1, IGL@, IL1B, IL1RN, IRF9, ITGA5, ITGAM, ITGB2, MCL1, MMP2, NCF2, P2RY1, PIK3CG, PTGS2, PTPRC, RELA, TK1, TLR2, TLR4 | |
| −3 | 1.8E-04 | CCL5, CCND1, CDKN1A, EDN1, GPX1, ICAM1, IFI16, IL1B, IL1RN, IL2RB, IL8, RPA3, STAT2 | |
| −3.1 | 1.6E-06 | CD83, CDKN1A, CXCL5, HLADRB1, ICAM1, IL1A, IL1B, IL8, MIA, PTGS2, RELB, SIRT1, TLR2, TLR4 | |
| −3.2 | 1.0E-06 | B2M, CASP1, CASP2, CCL5, CCND1, CDKN1A, CYBB, EIF4A3, HLA-G, IFIT3, IL1B, IL8, IRF1, IRF5, IRF7, IRF9, LTB, NFE2, PF4, PSMB10, PTGS2, SOCS7, STAT2, TRIM22 | |
| −3.4 | 1.5E-08 | ARPC3, ATP6V0B, BTG2, CCND1, CD3D, CD4, CD68, CD79A, CDH2, CEBPB, CYP19A1, CYP51A1, CYR61, DIO2, EDN1, EGR2, FN1, FOSB, GALNT1, HERPUD1, HLA-DRA, HLA-G, HMGCS1, HSPA4, IL1B, INHA, IRF7, MCL1, PDE3B, PDGFRA, PER1, PRL, PTGS2, SCD, SLC16A1, SLC2A4, SOD2, TF, TFAP2A, UPP1 | |
| −3.4 | 1.9E-08 | A2M, ADORA1, AKR1B1, B2M, BTG2, CCL5, CCND1, CDKN1A, COL2A1, CYBB, FANCD2, GATA3, GNB2L1, ICAM1, IER3, IFNGR2, IGHG1, IL1B, IL1RN, IL8, IRF1, LTB, MICA, NFKB1, NFKB2, PLK3, POU2F2, PRKACA, PTGS2, RELA, RELB, SOD2, TK1, TLR2, TNFAIP3 | |
| −3.7 | 3.1E-17 | A2M, ABCG2, ACTA2, AFP, B2M, BIRC2, BTG2, CAV1, CCL5, CCND1, CCR7, CD44, CDKN1A, COL2A1, CXCL1, CYBB, CYP19A1, DIO2, EDN1, EWSR1, F3, GDF15, HLA-B, ICAM1, IER2, IER3, IFNGR2, IGHG1, IL1A, IL1B, IL1RN, IL8, INPP5D, IRF1, IRF7, L | |
| −3.9 | 3.0E-03 | CASP4, CCL5, GBP1, IFI16, IFIT3, IRF1, IRF9, ISG20, ITGAM, MCL1, NAMPT, PSMB10, STAT2, TLR4, TMPO, TRIM21, TRIM22 | |
Abbreviation: TF, transcription factor/regulator.
Regulation z-score; P-value of overlap.
Figure 7Transcription factors predicted to be inhibited by battlefield-like stressors and their targets among stress-modulated genes. Shown here transcription factors predicted to be inhibited by battlefield stressors (Table 2) and their targets among 288 stress-affected transcripts (filtered using Welch's t-test and FDR, q<0.001, and >1.5-fold change). Enriched function and pathways of these transcripts include activation and proliferation of leukocytes, maturation of DCs, communication between innate and adaptive immunity, glucocorticoid receptor signaling and antigen presentation pathway.
Figure 8Functional network of differentially expressed genes connected by their sub-functions in the immune system. Network showing enriched functions of genes involved in the immune responses: activation of immune cells, differentiation, proliferation, antigen presentation and infection-directed migrations. Genes involved in all these functions were downregulated by the RASP stressors. Each node represents a category of gene ontology of the pathways of the immune system. Node sizes are proportional to the number of genes belonging to each category according to gene ontology, and the intensity of the node indicates significance of hypergeometric test after Bonferroni correction (q⩽0.05).
Figure 9Representations of role of suppressed transcripts in the immune responses. (a) Altered immune response genes involved in pattern recognition, viral, antibacterial and effector (humoral) responses. (b) Roles of stress downregulated genes in the cellular pathways of immune response: flat ended red arrows represent suppression of the corresponding pathway (biological process). Microbial recognition receptors, inflammatory cytokines (IL1, IL1R, TNFα, CD40), chemotaxis (IL8, IL8R, RANTES, CCR5, CCR7), lymphocyte recruitment (IL4, IL12) and production of effector molecules (INFγ, IL2, IL2RB) were downregulated in post-RASP leukocytes. (c) Actions of secreted cytokines on other leukocytes: impaired activity of suppressed IL-1 on other myeloid cells to secret antimicrobial effector molecules; depleted concentration gradient of IL-8 providing curtailed guidance to neutrophils and NK cells to sites of infection, and suppressed IL-8 and RANTES unable to recruit and induce maturation of dendritic cells (for antigen presentation). Suppressed transcripts important for T-cell polarization (cellular or humoral) may mean deprivation of the host under stress from having protective immunity.
Figure 10Stress-suppressed genes involved in antigen presentation and synapse formation. (a) Antigen presentation pathways: this KEEG pathway taken via IPA was colored for the 288 stress-regulated genes that passed Welch's t-test, FDR correction (q⩽0.001) and changed by ⩾1.5-fold (between pre- and post-RASP groups). (b) Expression of genes important for immunological synapse formation: suppression of transcripts important in antigen preparation, presentation, chemotaxis, intercellular binding, antigen reception and downstream signaling (green nodes) may impair formation of productive immunological synapse, which may explain the poor response of post-RASP leukocytes to SEB exposure; although SEB is presented without intracellular presentation, antigen presenting and receptor molecules of the synapse were suppressed.